Best Peptides for Muscle Growth and Fat Loss (2026): Ranked by Evidence

Quick answer: No peptide has been shown in a controlled human trial to build muscle and reduce fat together in healthy adults, and none is FDA-approved for muscle growth. Ranked by the strength of human evidence, the best-supported peptides for fat loss are the approved GLP-1 drugs (tirzepatide and semaglutide). The closest thing to a fat-down, lean-mass-up result is tesamorelin, which lowered visceral fat and raised DXA lean mass in adults with HIV lipodystrophy and has never been tested in healthy adults. Everything sold as a “lean muscle” or “recomp” peptide beyond those drugs rests on animal data, hormone levels or small studies. This guide ranks ten compounds by their trial evidence, tests the popular CJC-1295 plus ipamorelin “stack” claim against the literature, and lists the lot-level lab results Peptryn publishes for laboratory buyers.

Last reviewed October 3, 2026. Primary sources are listed at the end. For laboratory and research use only. Nothing here is medical or legal advice.

Best peptides for muscle growth and fat loss, ranked by evidence

A ranking has to say what it ranks. This one orders compounds into tiers by the strongest human evidence for a body-composition outcome: a randomized trial first, a body-composition measurement second, relevance to healthy adults third, and regulatory status last. Tier 1 is the strongest evidence and tier 5 the weakest. Tier 6 is a compound that was tested in people and failed. Popularity, forum buzz and vendor claims play no part.

Tier	Compound	Best human evidence	Fat-related result	Muscle-related result	Status
1	Tirzepatide	Randomized trials, SURMOUNT-1 DXA substudy (160 people)	Fat mass fell 33.9% vs 8.2% on placebo at week 72	None. Lean mass fell 10.9%	FDA-approved (Zepbound, Mounjaro)
1	Semaglutide	Randomized trials, STEP 1 DXA substudy (140 people)	About 8.4 kg of fat lost over 68 weeks	None. About 5.3 kg of lean mass lost	FDA-approved (Wegovy, Ozempic)
2	Tesamorelin	Two phase 3 randomized trials in HIV lipodystrophy	Visceral fat fell 15.2% vs a 5.0% rise on placebo (26 weeks)	DXA lean mass rose 1.3 kg vs a 0.2 kg fall on placebo. Strength not measured	FDA-approved (Egrifta), HIV lipodystrophy only
3	Retatrutide	Phase 2 body-composition substudy, type 2 diabetes (189 enrolled)	Fat mass fell 26.1% in the pooled 8 mg groups at 36 weeks	None. Lean mass fell	Investigational
4	Sermorelin	Hormone studies, plus two small 1997 body-composition studies in older adults	No fat-mass change in either study	Lean mass rose in men only in one 16-week study (19 adults), and did not change in a 6-week study	Brand (Geref) withdrawn in 2009
4	CJC-1295	Hormone-level studies in healthy adults (long-acting DAC form only)	None measured	None measured	Not approved
5	Ipamorelin	Animal studies, a healthy-volunteer hormone study, one failed phase 2 trial in bowel surgery	No body-composition data in people	None in people	Not approved
5	BPC-157, TB-500	Animal studies, one retrospective clinical report for BPC-157	None	None	Not approved
5	MOTS-c, 5-Amino-1MQ	Mouse studies	None in people	None in people	Not approved
6	AOD-9604	Phase IIb human obesity trial, disclosed 2007	Missed its primary endpoint	None	Not approved

These figures come from different trials, populations and durations. They are not a head-to-head comparison, and a larger number in one row does not mean a stronger drug. The table ranks how solid the evidence is, which decides whether a claim can be trusted.

The pattern is easy to state. Every compound with randomized fat-related human data is an approved or investigational prescription drug, and none of them has muscle-growth data in healthy adults. For identity and FDA-status detail on each compound, see our list of peptides and what they do.

Best peptides by goal

Goal	Best-supported compound	Limit that matters
Fat loss in obesity	Tirzepatide, semaglutide	Prescription drugs. Lean mass fell along with fat in both trials
Belly (visceral) fat	Tesamorelin	Tested in HIV lipodystrophy only, not in healthy adults
Muscle growth	None	No peptide has controlled-trial muscle data in healthy adults
Fat loss and muscle gain together	None	Growth hormone, a protein, did both in older adults, with side effects and no strength gain
Recovery	BPC-157, TB-500	Animal data only, plus one retrospective clinical report
Women, men	Same answer for both	None of the cited studies was built to test a muscle benefit in either sex

For the muscle-only side of the question, see our companion guide to peptides for muscle growth.

Peptides for fat loss: what the trials measured

“Peptides for fat loss” is one of the most-searched phrases in this field, and the answer is dominated by one class: GLP-1 pathway peptides. Their trials measure body weight and, in substudies, what the weight was made of.

Semaglutide: the STEP 1 body-composition substudy

Semaglutide is the active compound in Ozempic and Wegovy. In the STEP 1 DXA substudy (140 participants scanned; reported in the supplement to Wilding et al., New England Journal of Medicine, 2021, and in FDA’s Wegovy clinical review), the semaglutide group lost about 8.4 kg of fat mass and about 5.3 kg of lean mass over 68 weeks. The placebo group lost about 1.4 kg of fat and 1.8 kg of lean mass. Roughly two-fifths of the total loss on semaglutide was lean tissue. Lean mass on a DXA scan includes water and organ tissue, so this does not equal muscle loss, but it shows that a large fat reduction does not come with muscle preservation automatically.

Tirzepatide: the SURMOUNT-1 DXA substudy

Tirzepatide is the active compound in Mounjaro and Zepbound. A DXA substudy of SURMOUNT-1 (Look et al., Diabetes, Obesity and Metabolism, 2025; 160 participants; PMID 39996356) found that by week 72, body weight fell 21.3% on tirzepatide versus 5.3% on placebo (the tirzepatide group pools the 5, 10 and 15 mg arms, and only 160 of the trial’s 2,539 participants had both scans), fat mass fell 33.9% versus 8.2%, and lean mass fell 10.9% versus 2.6%. About 74% of the weight lost was fat and 26% was lean mass, close to the 75% and 25% split in the placebo group. The proportion stayed similar even as the total loss grew, which is the more reassuring reading, though the absolute amount of lean mass lost was still larger on the drug.

Retatrutide: a phase 2 body-composition substudy

Retatrutide is Eli Lilly’s investigational triple-pathway peptide. In a phase 2 body-composition substudy in adults with type 2 diabetes (189 participants; The Lancet Diabetes and Endocrinology, 2025; PMID 40609566), total body fat mass at 36 weeks fell by 26.1% in the pooled 8 mg retatrutide groups, versus 4.5% with placebo and 2.6% with dulaglutide (the 12 mg group fell 23.2%). Lean mass also fell, and the authors, all Lilly employees or shareholders, reported that the share of weight lost as lean mass was similar to that seen with other obesity treatments. Fewer participants completed both scans than enrolled, so the analyzed groups were smaller than 189. Retatrutide has not been filed with or approved by the FDA. See our retatrutide vs tirzepatide comparison for what each trial reported.

Across the class, a 2025 meta-analysis of seven placebo-controlled trials with DXA scans (659 participants; Beavers et al., Obesity) found that about 30% of the weight lost on GLP-1 receptor agonist therapy was lean mass. The DXA caveat matters here too: fat-free mass is mostly water, and organs and bone make up part of the rest, so skeletal muscle is a smaller quantity than the lean-mass number suggests (Tinsley and Heymsfield, Journal of the Endocrine Society, 2024).

What research is testing to protect muscle during weight loss

Because lean mass falls on GLP-1 drugs, drug makers are testing add-on treatments that aim to protect it. The point for this guide is that none of them is a peptide, and none is approved.

• Bimagrumab plus semaglutide (Eli Lilly). Bimagrumab is an antibody that blocks activin type II receptors, given by infusion. In the BELIEVE phase 2 trial (507 adults; Nature Medicine, 2026), DXA lean mass at week 48 changed by -1.1% to -2.6% in the combination groups, versus -5.3% to -7.9% with semaglutide alone. More people stopped treatment because of side effects in the bimagrumab groups (14.0% to 21.4% on bimagrumab alone, versus 3.6% to 8.8% on semaglutide alone).
• Apitegromab plus tirzepatide (Scholar Rock). Apitegromab is also an antibody. In the EMBRAZE phase 2 trial (102 adults, 24 weeks; Nature Medicine, 2026), lean mass fell 1.6 kg with apitegromab versus 3.5 kg with placebo, and fat loss was similar in both groups.
• Trevogrumab, with or without garetosmab, plus semaglutide (Regeneron). Both are antibodies. Regeneron reported 52-week phase 2 results from its COURAGE trial on October 1, 2026 and says a peer-reviewed paper is in press, so those numbers are company-reported for now.

Every result so far is phase 2, measured lean mass by DXA rather than muscle function, and comes from trials sponsored by the company that makes the drug. We found no approved drug for preserving muscle during weight loss. Until one exists, professional advice is the unglamorous kind. A 2025 joint advisory from four US nutrition and obesity societies recommends resistance training and attention to protein for people on GLP-1 therapy, and notes that protein targets of 1.2 to 1.6 g per kg per day have been proposed during active weight reduction. The American Diabetes Association’s 2026 Standards of Care say to optimize protein intake alongside resistance training. A clinician can tailor either to one person.

Best peptides for belly fat and visceral fat

Searches for the best peptides for belly fat loss and visceral fat loss point to one compound with real trial data: tesamorelin. In the 26-week randomized, placebo-controlled trial that led to its approval (Falutz et al., New England Journal of Medicine, 2007; PMID 18057338), visceral adipose tissue fell by 15.2% in the tesamorelin group and rose by 5.0% in the placebo group. Triglycerides fell by 50 mg per deciliter on tesamorelin and rose by 9 with placebo, and IGF-1 rose by 81%. A pooled analysis of two phase 3 trials (PMID 20554713) confirmed the visceral fat reduction with longer safety follow-up.

The same trial measured lean body mass by DXA. It rose by 1.3 kg on tesamorelin and fell by 0.2 kg on placebo, and the second phase 3 trial (Falutz et al., J Acquir Immune Defic Syndr, 2010; PMID 20101189) reported 1.2 kg versus 0.0 kg. That makes tesamorelin the one peptide in this guide with randomized data showing less visceral fat and more lean mass together. Three limits keep that from becoming a muscle claim. The participants were adults with HIV and excess abdominal fat from lipodystrophy, which is why Egrifta’s FDA approval (2010) covers that population only. DXA lean mass includes water and organ tissue, and the trial did not measure strength or muscle tissue directly. And visceral fat is the fat around internal organs, measured here by CT scan, so the trial did not test spot reduction of belly fat or any effect in healthy adults.

Best peptide stack for muscle growth and fat loss: what the evidence says

Searches for the “best peptide stack” lead mostly to one pairing, CJC-1295 with ipamorelin, and search summaries often call it the most effective stack for body recomposition. We searched PubMed and ClinicalTrials.gov on October 3, 2026 for a controlled human trial of that pair, or of any growth hormone-releasing hormone analog combined with a ghrelin-receptor agonist, with a body-composition, muscle or fat outcome. We found none. Here is what does exist.

CJC-1295. The long-acting DAC form raised growth hormone and IGF-1 in two randomized, placebo-controlled trials in healthy adults (Teichman et al., 2006; PMID 16352683), and two other small studies reported hormone levels or serum markers. None measured body composition. FDA’s 2024 briefing document says the one CJC-1295 trial aimed at a body-composition indication, a 12-week phase 2 study in HIV-associated visceral obesity, was stopped in 2006 after a participant died of a heart attack, that a link to the drug was not established, and that the results were never published. CJC-1295 without DAC, the shorter form usually sold for stacks, has no published human study. FDA’s briefing found that all three human studies used the DAC form.

Ipamorelin. The human record is a dose-escalation study in healthy men that measured growth hormone (Gobburu et al., 1999; PMID 10496658) and a phase 2 trial in 117 bowel-surgery patients that missed its primary goal (Beck et al., 2014; PMID 25331030). A second phase 2 trial with 320 participants has no posted results. No ipamorelin trial measured muscle or fat.

The two together. The closest human data are infusion studies showing that a growth hormone-releasing hormone analog plus a growth hormone-releasing peptide (GHRP-2) raised growth hormone more than either alone (Bowers et al., 2004; Van den Berghe et al., 1997), and one uncontrolled chart review of 14 men given sermorelin, GHRP-2 and GHRP-6 that reported IGF-1 only (Sigalos et al., 2017). All of them measured hormones. None measured muscle or fat. The same gap applies to the BPC-157 and TB-500 “Wolverine” blend, which has animal data and no human trial.

A higher growth hormone or IGF-1 reading is a hormone result, and a body-composition result is a separate finding that needs its own scan. The growth hormone evidence above shows what a real, sustained rise in growth hormone did in healthy older adults, and it came with side effects. Nothing shows that a peptide pairing reproduces that effect or avoids those costs. This guide gives no doses, timing or cycle lengths, because no controlled trial supports any. For a closer look at the pair, see our guide to CJC-1295 and ipamorelin.

Sermorelin vs ipamorelin vs CJC-1295

	Sermorelin	CJC-1295 (without DAC)	Ipamorelin
What it is	Growth hormone-releasing hormone analog (GHRH 1-29)	Growth hormone-releasing hormone analog, modified GRF 1-29	Ghrelin-receptor agonist (growth hormone secretagogue)
Human studies	Hormone studies, plus two small body-composition studies from 1997	None published	One healthy-volunteer hormone study, one failed phase 2 trial in bowel surgery
Body-composition trial in people	Yes, two small ones with mixed results	None	None
Compared head to head	No trial	No trial	No trial
FDA status	Geref approved 1990 (diagnostic) and 1997 (children with growth hormone deficiency), withdrawn in 2009 at the maker’s request	Not approved	Not approved
WADA 2026	Prohibited	Prohibited	Prohibited

Can peptides build muscle and reduce fat at the same time?

The only evidence base that shows both effects at once is for growth hormone itself, and it differs from what marketing describes. A 2007 systematic review of healthy older adults (Liu et al., Annals of Internal Medicine; 31 articles describing 18 study populations; 220 participants who received growth hormone and completed their studies; PMID 17227934) found lean body mass up about 2.1 kg and fat mass down about 2.1 kg, with no significant change in body weight. The treated groups had more soft tissue swelling, joint pain, carpal tunnel syndrome and gynecomastia, and somewhat more new-onset diabetes and impaired fasting glucose. A 2008 review of growth hormone and athletic performance in young, lean, fit adults (Liu et al.; 27 study samples, 303 people receiving growth hormone; PMID 18347346) concluded that lean mass appeared to increase but strength may not, exercise capacity may worsen, and adverse events increased.

Peptides that raise growth hormone are often marketed as a milder version of the same result. The human evidence for that claim is thin, and the stack section above covers what exists. A combined “muscle growth and fat loss” result from any of the research peptides in this guide is a hypothesis, not a finding.

Peptides for muscle growth before and after: why photos are not evidence

“Before and after” is one of the most-searched phrases in this topic, and it is where the gap between marketing and evidence is widest. A photo cannot separate a compound’s effect from everything else that changed:

• No control group. Nobody knows what the same person would have looked like over the same weeks without the compound.
• Conditions that change the picture. Lighting, pose, tan, muscle pump, hydration, posture and editing can all move a photo more than a few kilograms of tissue.
• Everything else changed too. Training, diet, sleep and body weight over the same period are almost never reported, and neither is any other substance the person was using.
• Selection. The photos that get published are the best responders, not a typical result.
• Unknown product. An unverified vial may not contain what its label says, which is why a lot-matched certificate of analysis matters (see what is a COA).

A real before-and-after in research is a measured baseline and follow-up, in many people, against a placebo group, using a scan that reports fat and lean mass in kilograms. The SURMOUNT-1 substudy above is exactly that. It shows a large fat reduction, a real lean-mass reduction, and a placebo group that also changed. No published trial provides a photo-style transformation for CJC-1295, ipamorelin, BPC-157 or TB-500.

FDA-approved peptides for fat loss and muscle growth

People searching for FDA-approved peptides for muscle growth are asking a question with a short answer: there are none. No peptide is FDA-approved to build muscle in healthy adults. The approved peptide drugs that touch body composition are approved for other purposes:

• Semaglutide (Wegovy, approved 2021) and tirzepatide (Zepbound, approved 2023) for chronic body-weight management in adults with obesity or overweight and related conditions.
• Liraglutide (Saxenda, approved 2014), an earlier GLP-1 pathway peptide for the same purpose.
• Setmelanotide (Imcivree, approved 2020), for obesity caused by certain rare genetic conditions.
• Tesamorelin (Egrifta, approved 2010), for excess abdominal fat in HIV-associated lipodystrophy.

None of the research peptides in this guide is approved for any use. In July 2026 an FDA advisory committee met on seven peptides and voted to recommend placing six of them (BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon) on the list of bulk substances that pharmacies may compound. The uses FDA evaluated were conditions such as ulcerative colitis, wound healing and insomnia, not muscle growth or fat loss. The vote is advisory, FDA said it does not intend to make a final determination until its reviews are finished, and as of October 3, 2026 we found no FDA action on it. In 2026 FDA also sent warning letters stating that a “research use only” label does not exempt a product from drug law when the seller’s marketing shows human use. See our peptide legality guide.

Are there safe peptides for muscle growth?

“Safe” would require long-term human safety data for a specific use, and for the compounds people search for alongside muscle growth, that data does not exist. The one systematic review of BPC-157 in orthopaedic sports medicine (Vasireddi et al., HSS Journal, 2025; PMID 40756949) found 35 preclinical studies and 1 clinical study out of 36, and reported that no clinical safety data were found. For growth hormone, the safety picture is documented and not favorable for healthy people: the 2007 and 2008 reviews above report soft tissue swelling, joint pain, carpal tunnel syndrome, higher rates of new-onset diabetes and impaired fasting glucose, and in young fit adults a possible drop in exercise capacity. For the GLP-1 class, the lean-mass findings above are a safety-relevant consideration for anyone with low muscle mass to begin with. The World Anti-Doping Agency’s 2026 Prohibited List bans growth hormone, the growth hormone-releasing peptides (including CJC-1295, sermorelin and tesamorelin), secretagogues such as ipamorelin, and TB-500 under its S2 category, and bans BPC-157 as a non-approved substance (S0), at all times in tested sport.

Oral peptides, peptide pills and over-the-counter peptides for muscle growth

Searches for oral peptides for muscle growth, peptide pills and over-the-counter peptides mix two different things.

Oral versions of the research peptides. Peptides are chains of amino acids, and the stomach and intestine are built to break chains of amino acids down. Oral semaglutide, the approved example in this class, is co-formulated with a permeation-enhancing ingredient (SNAC) to get absorbed at all, and its absorption is only about 1% (the FDA labels give a range of roughly 0.4% to 2% depending on the tablet). That is a purpose-built pharmaceutical tablet, and it says nothing about capsules sold as “muscle peptides.” Peptryn’s research materials are lyophilized powders for laboratory use, not oral products.

Over-the-counter “growth peptide” and protein supplements. These are dietary protein products. The best evidence on protein supplements comes from a 2018 meta-analysis (Morton et al., British Journal of Sports Medicine; 49 randomized trials, 1,863 participants; PMID 28698222), which found that protein supplementation during resistance training added about 0.30 kg of fat-free mass and 2.49 kg of one-repetition-max strength over training alone. That is a real but modest effect, and it is the ceiling for an ordinary protein supplement.

Lean muscle, recovery and “natural” peptides

Three more phrases show up constantly in this cluster, and each deserves a precise answer.

Peptides for lean muscle growth. “Lean” is a marketing adjective, not a measurement. The only human data on lean mass in this guide come from body-composition scans in growth hormone and GLP-1 trials. No peptide has been shown to add lean muscle in healthy adults in a controlled trial.

Peptides for muscle growth and recovery. Recovery claims mostly trace to BPC-157 and TB-500. The evidence is mostly animal work: the 2025 BPC-157 review covered 35 preclinical studies in muscle, tendon, ligament and bone injury models and 1 clinical study, a retrospective report on 12 people with chronic knee pain, and it found no clinical safety data. Animal injury models are not the same as recovery from training in a healthy person, and the review rates the underlying evidence as low level. See our BPC-157 guide and TB-500 guide.

Natural peptides for muscle growth. Peptides occur naturally in the body, and that is where the word gets its appeal. Growth hormone-releasing hormone and insulin are examples. A compound being related to a natural signal does not make a synthetic research version natural, safe or effective. Food-derived peptides, such as those in collagen or whey protein, are dietary protein, and the ordinary protein-supplement evidence above applies to them.

How to read a peptide study in five questions

Most peptide marketing borrows the language of a study without its limits. Five questions cut through most of it:

1. Who or what was studied? Cells, mice and people are three different levels of evidence, and people with a medical condition are not healthy adults.
2. What was measured? A rise in growth hormone or IGF-1 is a hormone result. Muscle size, strength and fat mass are different outcomes and need their own measurement.
3. Was there a placebo group? Without one, change over time cannot be attributed to the compound.
4. How long and how large? A few weeks in a small group says little about months of real-world use, and small studies tend to overstate effects.
5. Has it been replicated independently? Findings from a single research group, especially the same lineage for many years, carry less weight than repeated independent results.

Apply those five questions to any claim about the best peptides for muscle growth and fat loss and most of them dissolve. The claims that survive, such as tesamorelin’s visceral fat result and the GLP-1 class’s fat-mass results, are the ones backed by randomized trials with a placebo and a scan.

Forum threads fail the same test. Searches such as “best peptides for muscle growth reddit” show how much of this conversation happens in forums, and forum posts are useful for finding questions worth asking. They cannot answer them: there is no placebo group, the product identity is unverified, results are self-reported and self-selected, and other variables go unrecorded.

What has the best evidence for muscle and fat

The interventions with the strongest evidence for gaining muscle and losing fat are not peptides. Progressive resistance training drives muscle gain in healthy adults, and the protein meta-analysis above shows that protein intake adds a small, real increment on top of it. For people using GLP-1 pathway drugs, the lean-mass findings from STEP 1 and SURMOUNT-1 are the reason clinicians emphasize protein intake and resistance exercise alongside them. The section on muscle preservation above covers what professional advisories say about protein and resistance training with GLP-1 therapy.

Why no dose, timing or schedule appears in this guide: no controlled human trial has established a dose, timing, route or schedule of CJC-1295 without DAC, ipamorelin, BPC-157, TB-500, AOD-9604 or 5-Amino-1MQ for muscle growth or fat loss. The doses in the trials described above were supervised research or approved-drug protocols, and they do not transfer to self-administration. Any chart or schedule in circulation is extrapolated from animal work, vendor material or anecdote.

Research materials in this guide: lot data and what to check before you order

Peptryn lists several of the compounds above as laboratory research materials. They are sold for in-vitro laboratory research only, never for human or veterinary use, and you must be 21 or older to order. This section covers documentation, not effects. Price is a poor signal for a research material, because the cost a low-priced seller usually skips is testing.

Compound	Vial	Price	Lot purity (HPLC-UV-MS)	Endotoxin	Lot	Report
CJC-1295 no DAC	10mg	$99.99	99.11%	Negative	2026-08-05	COA
Ipamorelin	10mg	$89.99	99.34%	Negative	2026-08-05	COA
Sermorelin	10mg	$54.99	99.65%	Negative	2026-08-05	COA
5-Amino-1MQ	10mg	$64.99	99.86%	Negative	2026-08-05	COA
MOTS-c	40mg	$140.00	99.78%	Negative	2026-07-07	COA
BPC-157	10mg	$79.99	99.50%	Negative	2026-08-05	COA
TB-500	10mg	$89.99	99.84%	Negative	2026-08-05	COA
Wolverine blend (BPC-157 10mg + TB-500 10mg)	20mg	$200.00	99.13%	Negative	2026-08-05	COA

Lot results as published in Peptryn’s COA Library on October 8, 2026. Testing was done by MZ Biolabs, an independent third-party laboratory, on the lots listed. A report covers the lot it names, so match the lot on your order to the report before you rely on it. If a lot is not in the library, Peptryn’s lab-results page says you can request the report from support.

Five checks before you order from any research supplier

1. A lot-matched certificate of analysis. The report should name the lot or production date for what you receive, not a generic PDF reused across batches.
2. Identity as well as purity. HPLC measures purity. Mass spectrometry confirms the molecule is the one on the label. Look for both, and see how to read a certificate of analysis.
3. An endotoxin result. A purity percentage says nothing about bacterial endotoxin, so ask for that result too.
4. A named independent laboratory. A report from the seller’s own lab, or one with no lab named, is marketing. See peptide purity and peptide testing.
5. Claims that match the documentation. A supplier that promises muscle growth or fat loss from a research compound is making a claim the science does not support, and the guide above shows why.

Common questions

What are the best peptides for muscle growth and fat loss?

No peptide has been shown to build muscle and reduce fat together in healthy adults, so a ranking can only order the evidence. Tirzepatide and semaglutide rank first for fat loss, tesamorelin is next for visceral fat and lean mass in one approved population, and every other compound rests on animal data, hormone levels or small studies.

What are the best peptides for fat loss and muscle gain?

None has been proven to do both in healthy adults. Tesamorelin reduced visceral fat by 15.2% and raised DXA lean mass by 1.3 kg in adults with HIV lipodystrophy. Growth hormone raised lean mass by about 2.1 kg in older adults with more side effects, and the GLP-1 class reduced fat while also reducing lean mass.

Which peptides are best for muscle growth?

No peptide is approved for muscle growth, and none has controlled-trial muscle data in healthy adults. The compounds most often discussed are CJC-1295, ipamorelin, BPC-157 and TB-500, and their evidence is limited to hormone levels or animal studies. See our peptides for muscle growth guide.

What is the best peptide stack for muscle growth and fat loss?

No peptide stack has a controlled human trial with a body-composition result. CJC-1295 with ipamorelin is the pairing most often named, and our PubMed and ClinicalTrials.gov search on October 3, 2026 found no controlled trial of it and no published human study of CJC-1295 without DAC. This guide gives no doses, timing or cycles.

Do peptides work for muscle growth?

Not in any controlled human trial in healthy adults. The approved peptide drugs reduced fat and also reduced lean mass, tesamorelin raised DXA lean mass only in adults with HIV lipodystrophy, and the research peptides sold for muscle rest on animal data or hormone levels.

Does CJC-1295 really work?

In healthy adults, the long-acting DAC form raised growth hormone and IGF-1 levels in two randomized, placebo-controlled trials. That is a hormone result. No published study measured muscle or fat, and there is no published human study of the shorter without-DAC form.

Which is better, sermorelin or ipamorelin?

No trial has compared them. Sermorelin is a growth hormone-releasing hormone analog and ipamorelin is a ghrelin-receptor agonist, so they act on different receptors. Sermorelin has two small 1997 body-composition studies in older adults with mixed results, and ipamorelin has none.

Does sermorelin build muscle?

No controlled trial shows that it does in healthy adults. In a 16-week study of 19 older adults using a close variant of sermorelin, DXA lean mass rose in men only. In a 6-week study of older men, DXA muscle and fat did not change. FDA approved Geref (sermorelin) only for diagnostic and pediatric use, and the brand was withdrawn in 2009 at the maker’s request.

Does BPC-157 help muscle growth?

There is no controlled human trial of BPC-157 for muscle growth. A 2025 systematic review found 35 preclinical studies and one retrospective clinical report, in 12 people with knee pain, and no clinical safety data.

Which peptides should not be stacked?

No controlled trial has tested which peptide combinations are safe or unsafe, so no evidence-based list exists. The only chronic combination data in people are an uncontrolled chart review that measured IGF-1. This guide gives no combination advice.

What is the downside of taking peptides?

Long-term human safety is unknown for the research peptides here. FDA’s safety notes on CJC-1295 cite serious adverse events including increased heart rate and a systemic vasodilatory reaction, and a 2025 review found no clinical safety data for BPC-157. Growth hormone in healthy older adults caused soft tissue swelling, joint pain and carpal tunnel syndrome.

Do GLP-1 peptides cause muscle loss?

In the STEP 1 substudy, semaglutide reduced lean mass by about 5.3 kg alongside 8.4 kg of fat mass. In SURMOUNT-1, about 26% of the weight lost on tirzepatide was lean mass, and a 2025 meta-analysis put the class average near 30%. Lean mass on a DXA scan includes water and organ tissue, so it is not the same as skeletal muscle, but muscle is part of it.

What is the best peptide for belly fat or visceral fat?

Tesamorelin has the trial evidence, reducing visceral fat by 15.2% in adults with HIV-associated lipodystrophy, and it is approved only for that population. It has not been tested for belly fat in healthy adults.

Are there FDA-approved peptides for muscle growth?

No. Approved peptide drugs exist for obesity (semaglutide, tirzepatide, liraglutide, setmelanotide) and for abdominal fat in HIV lipodystrophy (tesamorelin), but none is approved to build muscle.

Do before and after photos prove peptides work?

No. Photos have no control group and cannot separate a compound’s effect from training, diet, lighting, pose, editing or other substances. Controlled trials with DXA scans and a placebo group are the meaningful before-and-after.

Do oral peptides or peptide pills build muscle?

There is no evidence that they do. Peptides are broken down in the digestive tract, and even purpose-built oral semaglutide is absorbed at only about 1% with the help of an absorption enhancer. Protein supplements added about 0.30 kg of fat-free mass in a large meta-analysis of resistance training.

Are peptides for muscle growth safe?

Long-term human safety has not been established for the research peptides discussed here. A 2025 systematic review found no clinical safety data for BPC-157, and growth hormone in healthy older adults was associated with soft tissue swelling, joint pain, carpal tunnel syndrome and more new-onset diabetes.

Are peptides for muscle growth different for women?

No peptide is approved for muscle growth in women or men, and none of the studies cited here was designed to test a muscle benefit in either sex.

How do you get peptides for muscle growth?

There is no approved route for muscle growth. Peptide drugs are prescribed by licensed providers for approved indications such as obesity or HIV-associated abdominal fat, and research-use-only suppliers sell materials to laboratories for in-vitro research, not for human use. See our guide to where peptides are sold and how the categories differ.

Are there natural peptides for muscle growth?

Peptides occur naturally in the body, but no natural or synthetic peptide has been shown to build muscle in healthy adults in a controlled trial. Food-derived protein supplements added about 0.30 kg of fat-free mass in a large meta-analysis of resistance training.

When should you take peptides for muscle growth?

No controlled human trial has established a timing, dose or schedule for any research peptide for muscle growth, so this guide does not provide one.

How much do research peptides cost, and how do you check quality?

Peptryn’s published prices for the compounds in this guide run from $54.99 for 10mg of sermorelin to $200.00 for the 20mg Wolverine blend, and every compound in the lot-data table above has a published lot report. A price far below that range with no lot-matched report usually means testing was skipped. Check the lot number, the purity method and the endotoxin result before you compare prices.

Related: Peptides for muscle growth · List of peptides and what they do · CJC-1295 and ipamorelin · What is a COA? · Popular peptides · Best peptides for men · Peptides for women · Peptides for weight loss

Sources

Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025;27(5):2720-2729 (PMID 39996356). Erratum (axis label only): 2025;27(11):6823. pubmed.ncbi.nlm.nih.gov

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989-1002, DXA subpopulation; and U.S. FDA Center for Drug Evaluation and Research clinical review, Wegovy (NDA 215256), Table 15. accessdata.fda.gov

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 randomised trial. The Lancet Diabetes and Endocrinology, 2025 (PMID 40609566). pubmed.ncbi.nlm.nih.gov

Beavers KM, et al. GLP-1RA-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity, 2025 (PMID 39710882). pubmed.ncbi.nlm.nih.gov

Tinsley GM, Heymsfield SB. Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. Journal of the Endocrine Society, 2024 (PMID 39372917). pubmed.ncbi.nlm.nih.gov

Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (BELIEVE). Nature Medicine, 2026;32(3):869-882 (PMID 41772149). pubmed.ncbi.nlm.nih.gov

Pratley RE, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine, 2026;32(7):2673-2678 (PMID 42260100). pubmed.ncbi.nlm.nih.gov

Regeneron Pharmaceuticals. Phase 2 COURAGE trial results, press release, October 1, 2026 (company-reported).

Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. 2025 (PMID 40445127). pubmed.ncbi.nlm.nih.gov

American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes-2026. Diabetes Care, 2026;49(Suppl 1):S166-S182 (PMID 41358882). pubmed.ncbi.nlm.nih.gov

Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357:2359-2370 (PMID 18057338). pubmed.ncbi.nlm.nih.gov

Falutz J, et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat (second phase 3 trial). Journal of Acquired Immune Deficiency Syndromes, 2010;53:311-322 (PMID 20101189). pubmed.ncbi.nlm.nih.gov

Falutz J, et al. Effects of tesamorelin: pooled analysis of two phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism, 2010;95:4291-4304 (PMID 20554713). pubmed.ncbi.nlm.nih.gov

U.S. Food and Drug Administration. Egrifta (tesamorelin) prescribing information. fda.gov

Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine, 2007;146:104-115 (PMID 17227934). pubmed.ncbi.nlm.nih.gov

Liu H, et al. Systematic review: the effects of growth hormone on athletic performance. Annals of Internal Medicine, 2008 (PMID 18347346). pubmed.ncbi.nlm.nih.gov

Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology and Metabolism, 1997;82:1472-1479 (PMID 9141536). pubmed.ncbi.nlm.nih.gov

Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism, 1997;46:89-96 (PMID 9005976). pubmed.ncbi.nlm.nih.gov

U.S. Food and Drug Administration. Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register, March 4, 2013. federalregister.gov

Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006 (PMID 16352683). pubmed.ncbi.nlm.nih.gov

U.S. Food and Drug Administration. Briefing document, Pharmacy Compounding Advisory Committee, December 4, 2024 (CJC-1295 related bulk drug substances). fda.gov

Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998 (PMID 9849822). pubmed.ncbi.nlm.nih.gov

Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 1999 (PMID 10496658). pubmed.ncbi.nlm.nih.gov

Beck DE, et al. Ipamorelin 201 Study Group. Int J Colorectal Dis, 2014 (PMID 25331030). pubmed.ncbi.nlm.nih.gov

Bowers CY, et al. Journal of Clinical Endocrinology and Metabolism, 2004;89:2290-2300 (PMID 15126555); Van den Berghe G, et al. Journal of Clinical Endocrinology and Metabolism, 1997;82:590-599 (PMID 9024260); Sigalos JT, et al. American Journal of Men’s Health, 2017 (PMID 28830317). pubmed.ncbi.nlm.nih.gov

Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology, 2001 (PMID 11713213). pubmed.ncbi.nlm.nih.gov

Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 2018 (PMID 29155147). pubmed.ncbi.nlm.nih.gov

Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015 (PMID 25738459). pubmed.ncbi.nlm.nih.gov

Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025 (PMID 40756949). pubmed.ncbi.nlm.nih.gov

Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine, 2018 (PMID 28698222). pubmed.ncbi.nlm.nih.gov

Current understanding of SNAC as an absorption enhancer: the oral semaglutide experience. Clinical Diabetes, 2024 (PMID 38230324). pubmed.ncbi.nlm.nih.gov

U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee, with FDA briefing and questions documents. The committee’s vote tallies were reported by law-firm and trade-press summaries because FDA had not posted a vote record when we checked on October 3, 2026. fda.gov

U.S. Food and Drug Administration. Warning letters to peptide sellers, August 24, 2026 (for example Peptide Partners LLC). fda.gov

World Anti-Doping Agency. 2026 Prohibited List, sections S0, S2.2 and S2.3. wada-ama.org

ClinicalTrials.gov. NCT00267527 (CJC-1295 in HIV-associated visceral obesity, terminated) and NCT00672074 (ipamorelin, postoperative ileus). clinicaltrials.gov

For laboratory research use only. Not for human or veterinary use, and not a drug, food, dietary supplement or cosmetic. You must be 21 or older to buy.